Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 4
1(33.3%)
3Total
Phase 2(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06399679Phase 2Recruiting

Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium

Role: collaborator

NCT06382649Phase 2Suspended

Rivastigmine for Antimuscarinic Delirium

Role: collaborator

NCT03090620Phase 4Completed

Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome

Role: collaborator

All 3 trials loaded